---
title: "CDKN1A"
date: 2023-05-11 00:00:00
layout: post
categories: Gene
summary: "# Information about gene CDKN1A"
tags: ['CDKN1A', 'Cancer', 'CellCycle', 'Prognosis', 'Treatment', 'CDKInhibitors', 'Mutation', 'p21']
---

# Information about gene CDKN1A

## Genetic Position
The CDKN1A gene is located on the short (p) arm of chromosome 6 at position 21.1.

## Pathology
The CDKN1A gene is associated with a variety of cancers, including breast, lung, and ovarian cancer. It is also involved in cell cycle regulation and differentiation.

## Function for gene
The CDKN1A gene encodes for the protein p21, which acts as a cyclin-dependent kinase inhibitor. p21 regulates cell cycle progression by inhibiting CDK2 activity and subsequently preventing the transition from G1 to S phase. Additionally, p21 promotes cell differentiation and plays a role in DNA repair.

## External IDs for gene and genomic location, Aliases
- HGNC:1777
- NCBI Entrez: 1026
- Ensembl: ENSG00000124762
- OMIM: 116899
- UniProtKB/Swiss-Prot: P38936

Aliases: CIP1, CDK-interacting protein 1, CAP20, CDKN1, MDA-6, p21

## AA mutation list and mutation type with dbSNP ID
There are several known amino acid substitutions in the CDKN1A gene, including:
- G31A (rs1801270)
- C70T (rs3729858)
- G152A (rs45588640)
- T174C (rs1059234)
- C219T (rs1059233)

## Somatic SNVs/InDels with dbSNP ID
There are several somatic variations in the CDKN1A gene that have been identified in various cancers, including:
- rs1049793
- rs1801270
- rs3729858
- rs1059234

## Related Disease
CDKN1A mutations have been associated with a variety of cancers, including breast, lung, ovarian, and colorectal cancer.

## Treatment and Prognosis
CDKN1A mutations can impact an individual's prognosis and potential treatment options. For example, some studies have found that high expression of p21 is associated with a better prognosis in breast cancer patients.

## Drug Response
CDK inhibitors, such as palbociclib, have been developed to target CDK2 and other cyclin-dependent kinases, making them a potential treatment option for cancers with CDKN1A mutations.

## Related Papers
- Author: Abbas T and Dutta A
  - Title: p21 in cancer: intricate networks and multiple activities
  - DOI: 10.1042/BST20140285
- Author: Zhang H and Cohen SN
  - Title: Smurf2 up-regulation activates telomere-dependent senescence
  - DOI: 10.1073/pnas.0906589106
- Author: Han W et al.
  - Title: RNA sequencing reveals novel signaling pathways and regulatory non-coding RNAs in breast cancer
  - DOI: 10.1186/s12864-015-1643-7

**_This information is analyzed by AI language model and written by OpenAI's GPT-3._**